Idorsia’s dual orexin receptor antagonist, the first and only drug of its kind approved in Europe for the treatment of ...
LYFT gains ground in the AV race with key alliances and stronger valuation metrics, outpacing WRD's global push.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback